What is claimed is:

1. A compound of a formula **I**:



I

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

(a) each occurrence of Z is independently $(CH_2)_m$, $(CH{=}CH)_t$, or phenyl, where each occurrence of m and t is an independent integer ranging from 1 to 9;

(b) G is $(CH_2)_x$, $CH_2CH{=}CHCH_2$, CH=CH, CH_2-phenyl-CH_2, or phenyl, where x is 2, 3, or 4;

(c) W^1 and W^2 are independently $C(R^1)(R^2)(CH_2)_n$-Y, V, $C(R^3)(R^4)$-$(CH_2)_c$-$C(R^5)(R^6)$-$(CH_2)_n$-Y, or $C(R^1)(R^2)$-$(CH_2)_c$-V where c is 1 or 2 and n is an integer ranging from 0 to 4;

(d) each occurrence of R^1 and R^2 is independently $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, phenyl, benzyl, or , R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(e) each occurrence of R^3 and R^4 is independently H, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, phenyl, benzyl, R^3 and R^4 and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(f) R^5 is H, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, $(C_1$-$C_6)$alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2, or CF_3;

(g) R^6 is OH, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, $(C_1$-$C_6)$alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2, or CF_3;

(h) V is



(i) each occurrence of Y is independently $(C_1$-$C_6)$alkyl, OH, COOH, CHO, $COOR^7$, SO_3H,



(j) R^7 is $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1\text{-}C_6)$alkoxy, or phenyl groups;

(k) each occurrence of R^8 is independently H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, or $(C_2\text{-}C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $(C_1\text{-}C_6)$alkoxy, or phenyl groups;

(l) each occurrence of R^9 is independently H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, or $(C_2\text{-}C_6)$alkynyl; and

(m) with the provisos:

(i) that when G is$(CH_2)_x$, then W^1 and W^2 cannot both be $C(R^1)(R^2)$–CHO or cannot both be



(ii) that when G is phenyl, then W^1 and W^2 cannot:

both be $C(R^1)(R^2)$–COOH,
both be $C(R^1)(R^2)$–CH_2OH,
both be $C(R^1)(R^2)$–$COOR^7$,
both be $(CH_2)_3$–C(H)(OH)–CH_2OH,
both be $(CH_2)_2$–C(H)(OH)–CH_2OH,
both be $C(R^1)(R^2)$–CHO, or
both be


, and

(iii) that when every occurrence of Z is phenyl, then W^1 and W^2 cannot both be $C(R^1)(R^2)$–OH.

2. The compound of claim 1, wherein W^1 and W^2 are independently $C(R^1)(R^2)(CH_2)_n$–Y, V, $C(R^3)(R^4)$–$(CH_2)_c$–$C(R^5)(R^6)$–Y, or $C(R^1)(R^2)$–$(CH_2)_c$–V.

3. The compound of claim 1, wherein W^1 and W^2 are independently $C(R^1)(R^2)(CH_2)_n$–Y, V, or $C(R^1)(R^2)$–$(CH_2)_c$–V.

4. The compound of claim 1, wherein W^1 and W^2 are independent $C(R^1)(R^2)(CH_2)_n$–Y groups.

5. The compound of claim 1, wherein W^1 is $C(R^1)(R^2)(CH_2)_n$–Y.

6. The compound of claim 1, wherein W^1 is V.

7. The compound of claim 1, wherein W^1 is $C(R^3)(R^4)$–$(CH_2)_c$–$C(R^5)(R^6)$–Y.

8. The compound of claim 1, wherein W^1 is $C(R^1)(R^2)$–$(CH_2)_c$–V.

9. The compound of claim 4, wherein each occurrence of Y is independently OH, $COOR^7$, or COOH.

10. The compound of claim 4, wherein each occurrence of Y is independently OH or COOH.

11. The compound of claim 1, wherein m is an integer ranging from 1 to 4 and t is 1.

12. The compound of claim 1, wherein R^6 is OH, $(C_1$–$C_6)$alkyl, $(C_2$–$C_6)$alkenyl, $(C_2$–$C_6)$alkynyl, $(C_1$–$C_6)$alkoxy, phenyl, benzyl, Cl, or Br.

13. A compound of a formula **Ia**:



Ia

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

(a) each occurrence of Z is independently $(CH_2)_m$ or $(CH{=}CH)_t$, where each occurrence of m and t is an independent integer ranging from 1 to 9;

(b) G is $(CH_2)_x$, $CH_2CH{=}CHCH_2$, or CH=CH, where x is 2, 3, or 4;

(c) W^1 and W^2 are independently $C(R^1)(R^2)(CH_2)_n$–Y, V, or $C(R^1)(R^2)$–$(CH_2)_c$–V, where c is 1 or 2 and n is an integer ranging from 0 to 4;

(d) each occurrence of R^1 and R^2 is independently $(C_1$–$C_6)$alkyl, $(C_2$–$C_6)$alkenyl, $(C_2$–$C_6)$alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(e) V is



(f) each occurrence of Y is independently OH, COOH, CHO, $COOR^7$, SO_3H,





(g) R^7 is $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1\text{-}C_6)$alkoxy, or phenyl groups;

(h) each occurrence of R^8 is independently H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, or $(C_2\text{-}C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $(C_1\text{-}C_6)$alkoxy, or phenyl groups;

(i) each occurrence of R^9 is independently H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, or $(C_2\text{-}C_6)$alkynyl; and

(j) with the proviso that when G is$(CH_2)_x$, then W^1 and W^2 cannot both be $C(R^1)(R^2)$–CHO or cannot both be



14. The compound of claim 13, wherein W^1 and W^2 are independent $C(R^1)(R^2)(CH_2)_n$–Y groups.

15. The compound of claim 13, wherein W^1 is $C(R^1)(R^2)(CH_2)_n$–Y.

16. The compound of claim 13, wherein W^1 is V.

17. The compound of claim 13, wherein W^1 is $C(R^1)(R^2)$–$(CH_2)_c$–V.

18. The compound of claim 14, wherein each occurrence of Y is independently OH, $COOR^7$, or COOH.

19. The compound of claim 14, wherein each occurrence of Y is independently OH or COOH.

20. The compound of claim 13, wherein m is an integer ranging from 1 to 4 and t is 1.

21. A compound of the formula **Ib**



Ib

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

(a) each occurrence of m is independently an integer ranging from 1 to 9;

(b) each occurrence of n is an independent integer ranging from 0 to 4;

(c) x is 2, 3, or 4;

(d) each occurrence of R^1 and R^2 is independently $(C_1$–$C_6)$alkyl, $(C_2$–$C_6)$alkenyl, $(C_2$–$C_6)$alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(e) each occurrence of R^{11} and R^{12} and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(f) Y^1 and Y^2 are independently $(C_1$–$C_6)$alkyl, OH, COOH, CHO, $COOR^7$, SO_3H,



(g) R^7 is $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1$-$C_6)$alkoxy, or phenyl groups;

(h) each occurrence of R^8 is independently H, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $(C_1$-$C_6)$alkoxy, or phenyl groups;

(i) each occurrence of R^9 is independently H, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl; and

(j) with the proviso that both occurrences of Y cannot both be CHO.

22. The compound of claim 21, wherein each occurrence of Y is independently OH, $COOR^7$, or COOH.

23. The compound of claim 21, wherein each occurrence of Y is independently OH or COOH.

24. The compound of claim 22, wherein each occurrence of R^1 or R^2 is independently $(C_1$-$C_6)$alkyl group.

25. The compound of claim 22, wherein each occurrence of R^1 or R^2 is methyl.

26. A compound of the formula **Ic**



Ic

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

(a) each occurrence of m is an independent integer ranging from 1 to 9;

(b) x is 2, 3, or 4;

(c) V is



27. A compound of a formula **Id**:



Id

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein

(a) each occurrence of m is independently an integer ranging from 1 to 9;

(b) each occurrence of n is an independent integer ranging from 0 to 4;

(c) x is 2, 3, or 4;

(d) each occurrence of R^1 is independently $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, or benzyl;

(e) each occurrence of Y is $(C_1\text{-}C_6)$alkyl, OH, COOH, CHO, $COOR^7$, SO_3H,





(f) R^7 is H, (C_1-C_4) alkyl, phenyl, or benzyl, and is substituted or unsubstituted with one or more halo, OH, (C_1-C_6)alkoxy, or phenyl groups;

(g) each occurrence of R^8 is independently H, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, or (C_2-C_6)alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6)alkoxy, or phenyl groups;

(h) each occurrence of R^9 is independently H, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, or (C_2-C_6)alkynyl;

(i) R^{10} and R^{11} are independently H, halogen, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_6)aryl, (C_6)aryloxy, CN, or NO_2, $N(R^7)_2$.

28. A compound of the formula:

I-114 4-[3-(3-carboxy-3-methyl-butoxy)-propoxy]-2,2-dimethyl-butyric acid,

I-297 5-[2-(5-hydroxy-4,4-dimethyl-pentyloxy)-ethoxy]-2,2-dimethyl-pentan-1-ol,

IV-1 3-{3-[3-(2-Carboxy-2-methyl-propyl)-phenoxy]-phenyl}-2,2-dimethyl-propionic acid,

IV-2 1-{3-[3-(2-hydroxy-2-methyl-propyl)-phenoxy]-phenyl}-2-methyl-propan-2-ol,

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or a mixture of stereoisomer thereof.

29. A compound of the formula:

I-1: 4-[2-(3-hydroxy-3-methyl-butoxy)-ethoxy]-2-methyl-butan-2-ol;

I-2: 4-[2-(4-hydroxy-3,3-dimethyl-butoxy)-ethoxy]-2,2-dimethyl-butan-1-ol;

I-3: 4-[2-(3-carboxy-3-methyl-butoxy)-ethoxy]-2,2-dimethyl-butyric acid;

I-4: 4-[2-(3,3-dimethyl-4-oxo-butoxy)-ethoxy]-2,2-dimethyl-butanal;

I-5: 4-[2-(3-methoxycarbonyl-3-methyl-butoxy)-ethoxy]-2,2-dimethyl-butyric acid methyl ester;

I-6: 2,2-dimethyl-4-[2-(3-methyl-3-phenoxycarbonyl-butoxy)-ethoxy]-butyric acid phenyl ester;

I-7: benzyl-2,2,2',2'-tetramethyl-4,4'-[ethylenebis(oxadiyl)]dibutryrate;

I-8: 2,2'-dimethyl-4,4'-[ethylenebis(oxadiyl)]dibutane-2-sulfonic acid;

I-9: phosphoric acid mono-{3-[2-(3,3-dimethyl-butoxy)-ethoxy]-1,1- dimethyl-propyl} ester;

I-10: 1-ethyl-3-(3-{2-[3-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-c] pyridin-5-yl))-3-methyl-butoxy]-ethoxy}-1,1-dimethyl-propyl)-4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-c]pyridin-5-yl-4,6-dione;

I-11: 1-ethyl-3-(3-{2-[3-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-c] pyridin-5-yl))-3-methyl-butoxy]-ethoxy}-1,1-dimethyl-propyl)-4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-c]pyridin-5-yl-4,6-dithione;

I-12: 2,2-dimethyl-4-[2-(3-methyl-3-cyanocarbamoyl-butoxy)-ethoxy]-*N*-cyano-butyramide;

I-13: phosphoradimic acid mono-(3-{2-[3-(amino-hydroxy-phosphoryloxy)-3-methyl-butoxy]-ethoxy}-1,1-dimethyl-propyl) ester;

I-14: {1,1-dimethyl-3-[2-(3-methyl-3-phosphonamido-butoxy)-ethoxy]-propyl}-phosphonic acid amide;

I-15: 1-{3-[2-(3-methyl-3-{(1*H*)-tetrazol-1-yl}-butoxy)-ethoxy]-1,1-dimethyl-propyl}-1*H*-tetrazole;

I-16: 5-{3-[2-(3-methyl-3-{(1*H*)tetrazol-5-yl}-butoxy)-ethoxy]-1,1-dimethyl-propyl}-1*H*-tetrazole;

I-17: 1-ethyl-3-(3-{2-[3-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3-methyl-butoxy]-ethoxy}-1,1-dimethyl-propyl)-imidazolidine-2,4-dione;

I-18: 1-ethyl-3-(3-{2-[3-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3-methyl-butoxy]-ethoxy}-1,1-dimethyl-propyl)-imidazolidine-2,4-dione;

I-19: 1-ethyl-3-(3-{2-[3-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-3- methyl-butoxy]-ethoxy}-1,1-dimethyl-propyl)-imidazolidine-2-thioxo-4-one;

I-20: 1-ethyl-3-(3-{2-[3-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)- 3-methyl-butoxy]-ethoxy}-1,1-dimethyl-propyl)-imidazolidine-4-thioxo-2-one;

I-21: 1-{3-[2-(3-methyl-3-(3-methyl-isoxazol-5-yl)-butoxy)-ethoxy]-1,1-dimethyl-propyl}-5-isoxazole;

I-22: 1-{3-[2-(3-methyl-3-(3-methyl-isoxazol-4-yl)-butoxy)-ethoxy]-1,1-dimethyl-propyl}-4-isoxazole;

I-23: 3-{3-[2-(3-methyl-3-(5-hydroxy-pyran-3-yl-4-one)-butoxy)-ethoxy]-1,1-dimethyl-propyl}-5-hydroxy-pyran-4-one;

I-24: 2-{3-(2-[3-methyl-3-(5-hydroxy-pyran-2-yl-4-one)-butoxy]-ethoxy)]-1,1-dimethyl-propyl}-5-hydroxy-pyran-4-one;

I-25: 2-{3-[2-(3-methyl-3-(5-hydroxy-pyran-3-yl-4-one)-butoxy]-ethoxy}-1,1-dimethyl-propyl}-5-hydroxy-pyran-4-one;

I-26: 1-(2-tetrahydropyranyloxy)-2-{2-[2-(2-tetrahydropyranyloxy)-ethoxy]-ethoxy}ethane;

I-27: 4-{2-[2-(4-oxetan-2-one)-propoxy-ethoxy]-ethyl}-oxetan-2-one;

I-28: 3-{2-[2-(3-oxetan-2-one)-propoxy-ethoxy]-ethyl}-oxetan-2-one;

I-29: 5-{2-[2-(5-dihydro-furan-2-one)-propoxy-ethoxy]-ethyl}-dihydro-furan-2-one;

I-30: 4-{2-[2-(4-dihydro-furan-2-one)-propoxy-ethoxy]-ethyl}-dihydro-furan-2-one;

I-31: 3-{2-[2-(3-dihydro-furan-2-one)-propoxy-ethoxy]-ethyl}-dihydro-furan-2-one;

I-32: 2-{2-[2-(2-{2-[4-(carboxy-methyl)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl]-ethoxy}-ethoxy)-ethyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid;

I-33: 2,2'-[ethylenebis(oxadiyl)]diethane-6-d-valerolactone;

I-34: 2,2'-[ethylenebis(oxadiyl)]diethane-5-d-valerolactone;

I-35: 2,2'-[ethylenebis(oxadiyl)]diethane-4-d-valerolactone;

I-36: 2,2'-[ethylenebis(oxadiyl)]diethane-3-d-valerolactone;

I-37: 3,3,3',3'-tetramethyl-5,5'-[ethylenebis(oxadiyl)]dipentanol;

I-38: 3,3,3',3'-tetramethyl-5,5'-[ethylenebis(oxadiyl)]dipentanoic acid;

I-39: 3,3,3',3'-tetramethyl-5,5'-[ethylenebis(oxadiyl)]dipentanal;

I-40: methyl-3,3,3',3'-tetramethyl-5,5'-[ethylenebis(oxadiyl)]dipentanoate;

I-41: phenyl-3,3,3',3'-tetramethyl-5,5'-[ethylenebis(oxadiyl)]dipentanoate;

I-42: benzyl-3,3,3',3'-tetramethyl-5,5'-[ethylenebis(oxadiyl)]dipentanoate;

I-43: 4,4,4',4'-tetramethyl-6,6'-[ethylenebis(oxadiyl)]dihexanol;

I-44: 4,4,4',4'-tetramethyl-6,6'-[ethylenebis(oxadiyl)]dihexanoic acid;

I-45: 4,4,4',4'-tetramethyl-6,6'-[ethylenebis(oxadiyl)]dihexanal;

I-46: methyl-4,4,4',4'-tetramethyl-6,6'-[ethylene-(oxadiyl)]-dihexanoate;

I-47: phenyl-4,4,4',4'-tetramethyl-6,6'-[ethylenebis(oxadiyl)]dihexanoate;

I-48: benzyl-4,4,4',4'-tetramethyl-6,6'-[ethylenebis(oxadiyl)]dihexanoate;

I-49: 2,2,2',2'-tetramethyl-4,4'-[ethylenebis(oxadiyl)]dibutane sulfonic acid;

I-50: phosphoric acid mono-{4-[2-(3,3-dimethyl-4-phosphonooxy-butoxy)-ethoxy]-2,2-dimethyl-butyl}ester;

I-51: 5-{4-[2-(3,3-dimethyl-4-(5-(3,3a-dihydro-2*H*-thieno-[3,2-c]pyridine-4,6-dioxo)pentyloxy)-ethoxy]-2,2-dimethyl-butyl}- 3,3a-dihydro 3,3a-dihydro-2*H*-thieno-[3,2-c]pyridine-4,6-dione;

I-52: 5-{4-[2-(3,3-dimethyl-4-(5-(3,3a-dihydro-2*H*-thieno-[3,2-c]pyridine-4,6-dithioxo)pentyloxy)-ethoxy]-2,2-dimethyl-butyl}- 3,3a-dihydro3,3a-dihydro-2*H*-thieno-[3,2-c]pyridine-4,6-dithione;

I-53: 5-[2-(3,3-dimethyl-4-cyanocarbamoyl-butoxy)-ethoxy]-3,3-dimethyl-*N*-cyano-pentanoic acid-amide;

I-54: phosphoramidic acid mono-(4-{2-[4-(amino-hydroxy-phosphoryloxy)-3,3-dimethyl-butoxy]-ethoxy}-2,2-dimethyl-butyl) ester;

I-55: {4-[2-(3,3-dimethyl-4-phosphonamido-butoxy)-ethoxy]-2,2-dimethyl-butyl}-phosphonamide;

I-56: 1-{4-[2-(3,3-dimethyl-5-{1*H*-tetrazol-1-yl}-butoxy)-ethoxy]-2,2-dimethyl-butyl}-1*H*-tetrazole;

I-57: 5-{4-[2-(3,3-dimethyl-5-{1*H*-tetrazol-5-yl}-butoxy)-ethoxy]-2,2-dimethyl-butyl}-1*H*-tetrazole;

I-58: 5-{4-[2-(3,3-dimethyl-5-{3-hydroxy-isoxazol-5-yl}-butoxy)-ethoxy]-2,2-dimethyl-butyl}-3-hydroxy-isoxazole;

I-59: 4-{4-[2-(3,3-dimethyl-5-{3-hydroxy-isoxazol-4-yl}-butoxy)-ethoxy]-2,2-dimethyl-butyl}-3-hydroxy-isoxazole;

I-60: 2-{4-[2-(3,3-dimethyl-5-{5-hydroxy-pyran-4-oxo-3-yl}-butyloxy)-ethoxy]-2,2-dimethyl-butyl}-5-hydroxy-pyran-4-one;

I-61: 2-{4-[2-(3,3-dimethyl-5-{5-hydroxy-pyran-4-oxo-2-yl}-butyloxy)-ethoxy]-2,2-dimethyl-butyl}-5-hydroxy-pyran-4-one;

I-62: 3-{4-[2-(3,3-dimethyl-5-{5-hydroxy-pyran-4-oxo-3-yl}-butyloxy)-ethoxy]-2,2-dimethyl-butyl}-5-hydroxy-pyran-4-one;

I-63: 1-ethyl-3-(4-{2-[4-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3-dimethyl-butoxy]-ethoxy}-2,2-dimethyl-butyl)-imidazolidine-2,4-dione;

I-64: 1-ethyl-3-(4-{2-[4-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3,3-dimethyl-butoxy]-ethoxy}-2,2-dimethyl-butyl)-imidazolidine-2,4-dione;

I-65: 1-ethyl-3-(4-{2-[4-(3-ethyl-2-thioxo-4-oxo-imidazolidin- 1-yl)-3,3-dimethyl -butoxy]-ethoxy}-2,2-dimethyl-butyl)-imidazolidine-2-thioxo-4-one;

I-66: 1-ethyl-3-(4-{2-[4-(3-ethyl-2-oxo-4-thioxo-imidazolidin-1-yl)-3,3-dimethyl-butoxy]-ethoxy}-2,2-dimethyl-butyl)-imidazolidine-2- oxo-4-thione;

I-67: 3,3,3',3'-tetramethyl-5,5'-[ethylenebis(oxadiyl)]dipentane sulfonic acid;

I-68: phosphoric acid mono-{1,1-dimethyl-3-[2-(3-methyl-3-phosphonooxy-butoxy)-ethoxy]-propyl}ester;

I-69: 5-(5-{2-[3,3-dimethyl-5-(4,6-dioxo-2,3,3a,6-tetrahydro-4h-thieno-[3,2-c]pyridin-5-yl)-pentyloxy]-ethoxy}-3,3-dimethyl-pentyl)-3,3a-dihydro-2*H*-thieno[3,2-c] pyridine-4,6-dione;

I-70: 5-(5-{2-[3,3-dimethyl-5-(4,6-dithioxo-2,3,3a,6-tetrahydro-4h- thieno[3,2-c]pyridin-5-yl)-pentyloxy]-ethoxy}-3,3-dimethyl- pentyl)-3,3a-dihydro-2*H*-thieno[3,2-c]pyridine-4,6-dione;

I-71: 6-[2-(3,3-dimethyl-5-cyano-carbamoyl-butoxy)-ethoxy]-4,4-dimethyl-*N*-cyano-hexanoic acid-amide;

I-72: phosphoramidic acid mono-(5-{2-[5- (amino-hydroxy-phosphoryloxy)- 3,3-dimethyl-pentyloxy]-ethoxy}-3,3-dimethyl-pentyl) ester;

I-73: {5-[2-(3,3-dimethyl-5-phosphonamido-pentyloxy)-ethoxy]- 3,3-dimethyl-pentyl}-phosphonamide;

I-74: 1-{[2-(3,3-dimethyl-5-tetrazol-1-yl-pentyloxy)-ethoxy]-3,3-dimethyl-pentyl}-1*H*-tetrazole;

I-75: 5-{5-[2-(3,3-dimethyl-5-tetrazol-1-yl-pentyloxy)-ethoxy]-3,3-dimethyl-pentyl}-1*H*-tetrazole;

I-76: 5-{5-[2-(3,3-dimethyl-5-{3-hydroxy-isoxazol-5-yl}-pentyloxy) -ethoxy] -3,3-dimethyl-pentyl}-isoxazol-3-ol;

I-77: 4-{5-[2-(3,3-dimethyl-5-{3-hydroxy-isoxazol-4-yl}-pentyloxy)- ethoxy] - 3,3-dimethyl-pentyl}-isoxazol-3-ol;

I-78: 3-{5-[2-(5-{5-hydroxy-4-oxo-4*H*-pyran-2-yl}-3,3-dimethyl-pentyloxy)-3,3-dimethyl-pentyl]-5-hydroxy-pyran-4-one;

I-79: 2-{5-[2-(5-{5-hydroxy-4-oxo-4*H*-pyran-2-yl}-3,3-dimethyl-pentyloxy)-3,3-dimethyl-pentyl]-5-hydroxy-pyran-4-one;

I-80: 3-{5-[2-(5-{5-hydroxy-4-oxo-4*H*-pyran-3-yl}-3,3-dimethyl-pentyloxy)-3,3-dimethyl-pentyl]-5-hydroxy-pyran-4-one;

I-81: 1-ethyl-3-(5-{2-[5-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)- 3,3-dimethyl-pentyloxy]-ethoxy}-3,3-dimethyl-pentyl)-imidazolidine- 2,4-dione;

I-82: 1-ethyl-3-(5-{2-[5-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3,3-dimethyl-pentyloxy]-ethoxy}-3,3-dimethyl-pentyl)-imidazolidine-2,4-dione;

I-83: 1-ethyl-3-(5-{2-[5-(1-ethyl-2-thioxo-5-oxo-imidazolidin-3-yl)-3,3-dimethyl-pentyloxy]-ethoxy}-3,3-dimethyl-pentyl)-imidazolidine-2-thioxo-4-one;

I-84: 1-ethyl-3-(5-{2-[5-(1-ethyl-2-oxo-5-thioxo-imidazolidin-3-yl)-3,3-dimethyl-pentyloxy]-ethoxy}-3,3-dimethyl-pentyl)-imidazolidine-2-oxo-4-thione;

I-85: 4-[4-(3-hydroxy-3-methyl-butoxymethyl)-benzyloxy]-2-methyl-butan-2-ol;

I-86: 4-[4-(4-hydroxy-3,3-dimethyl-butoxymethyl)-benzyloxy]-2,2-dimethyl-butan-1-ol;

I-87: 4-[4-(3-carboxyl-3,3-dimethyl-butoxymethyl)-benzyloxy]-2,2-dimethyl-butyric acid;

I-88: 4-[4-(4-hydroxy-3,3-dimethyl-butoxymethyl)-benzyloxy]-2,2-dimethyl-butanal;

I-89: 4-[4-(3,3-dimethyl-3-carboxymethyl-butoxymethyl)-benzyloxy]-2,2-dimethyl-butyric acid methyl ester;

I-90: 2,2-dimethyl-4-[4-(3-methyl-3-phenoxycarbonyl-butoxymethyl)-benzyloxy]-butyric acid phenyl ester;

I-91: 4-[4-(3-benzyloxycarbonyl-3-methyl-butoxymethyl)-benzyloxy]-2,2-dimethyl-butyric acid benzyl ester;

I-92: 2,2'-dimethyl-4,4'-[vinylbis(oxadiyl)]dibutane-2-sulfonic acid;

I-93: phosphoric acid mono-{1,1-dimethyl-3-[4-(3-methyl-3-phosphonooxy-butoxymethyl)-benzyloxy]-propyl}ester;

I-94: 2,2'-dimethyl-4,4'-[vinylbis(oxadiyl)]dibutanol;

I-95: 4-[2-(4-hydroxy-3,3-dimethyl-butoxy)-vinyloxy]-2,2-dimethyl-butan-1-ol;

I-96: 4-[2-(3-carboxyl-3,3-dimethyl-butoxy)-vinyloxy]-2,2-dimethyl-butyric acid;

I-97: 4-[2-(4-hydroxy-3,3-dimethyl-butoxy)-vinyloxy]-2,2-dimethyl-butanal;

I-98: 4-[2-(3,3-dimethyl-3-carboxymethyl-3-butoxy)-vinyloxy]-2,2-dimethyl-butyric acid methyl ester;

I-99: 2,2-dimethyl-4-[2-(3-methyl-3-phenoxycarbonyl-butoxy)-vinyloxy]-butyric acid phenyl ester;

I-100: 2,2-dimethyl-4-[2-(3-methyl-3-benzyloxycarbonyl-butoxy)-vinyloxy]-butyric acid benzyl ester;

I-101: 4-[2-(3,3-dimethyl-3-sulfono-butoxy)-vinyloxy]-2-methyl-butane-2-sulfonic acid;

I-102: phosphoric acid mono-{3-[2-(3,3-dimethyl-butoxy)-vinyloxy]-1,1-dimethyl-propyl} ester;

I-103: 4-[4-(3-hydroxy-3-methyl-butoxy)-phenoxy]-2-methyl-butan-2-ol;

I-104: 4-[4-(4-hydroxy-3,3-dimethyl-butoxy)-phenoxy]-2,2-dimethyl-butan-1-ol;

I-105: 4-[4-(3-carboxyl-3,3-dimethyl-butoxy)-phenoxy]-2,2-dimethyl-butyric acid;

I-106: 4-[4-(4-hydroxy-3,3-dimethyl-butoxy)-phenoxy]-2,2-dimethyl-butanal;

I-107: 4-[4-(3,3-dimethyl-3-carboxymethyl-butoxy)-phenoxy]-2,2-dimethyl-butyric acid methyl ester;

I-108: 2,2-dimethyl-4-[4-(3-methyl-3-phenoxycarbonyl-butoxy)-phenoxy]-butyric acid phenyl ester;

I-109: 4-[4-(3-benzyloxycarbonyl-3-methyl-butoxy)-phenoxy]-2,2-dimethyl-butyric acid benzyl ester;

I-110: 4-[4-(3,3-dimethyl-3-sulfono-butoxy)-phenoxy]-2-methyl-butane-2-sulfonic acid;

I-111: 4-[4-(3,3-dimethyl-3-oxyphosphono-butoxy)-phenoxy]-2-methyl-butane-2-oxyphosphoric acid;

I-112: 4-[3-(3-hydroxy-3-methyl-butoxy)-propoxy]-2-methyl-butan-2-ol;

I-113: 4-[3-(4-hydroxy-3,3-dimethyl-butoxy)-propoxy]-2,2-dimethyl-butan-1-ol;

I-114: 4-[3-(3-carboxy-3-methyl-butoxy)-propoxy]-2,2-dimethyl-butyric acid;

I-115: 4-[3-(3,3-dimethyl-4-oxo-butoxy)-propoxy]-2,2-dimethyl-butanal;

I-116: 4-[3-(3-Methoxycarbonyl-3-methyl-butoxy)-propoxy]-2,2-dimethyl-butyric acid methyl ester;

I-117: 4-[3-(3,3-dimethyl-4-oxo-5-phenyl-pentyloxy)-propoxy]-2,2-dimethyl-butyric acid phenyl ester;

I-118: 4-[3-(3-benzyloxycarbonyl-3-methyl-butoxy)-propoxy]-2,2-dimethyl-butyric acid benzyl ester;

I-119: 2-methyl-4-[3-(3-methyl-3-sulfo-butoxy)-propoxy]-butane-2-sulfonic acid;

I-120: phosphoric acid mono-{1,1-dimethyl-3-[3-(3-methyl-3- phosphonooxy-butoxy)-propoxy]-propyl} ester;

I-121: 1-ethyl-3-(3-{3-[3-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-c]pyridin-5-yl))-3-methyl-butoxy]-propoxy}-1,1-dimethyl-propyl)-4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-c]pyridin-5-yl-4,6-dione;

I-122: 1-ethyl-3-(3-{3-[3-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-c]pyridin-5-yl))-3-methyl-butoxy]-propoxy}-1,1-dimethyl-propyl)-4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-c]pyridin-5-yl-4,6-dithione;

I-123: 2,2-dimethyl-4-[3-(3-methyl-3-cyano-carbamoyl-butoxy)-propoxy]-*N*-cyano-butyric acid-amide;

I-124: phosphoramidic acid mono-(3-{3-[3-(amino-hydroxy-phosphoryloxy)-3-methyl-butoxy]-propoxy}-1,1-dimethyl-propyl) ester;

I-125: {1,1-dimethyl-3-[3-(3-(methyl-3-phosponamido-butoxy)-propoxy]-propyl}-phosphonamide;

I-126: 1-{3-[3-(3-methyl-3-tetrazol-1-yl-butoxy)-propoxy]-1,1-dimethyl-propyl}-1*H*-tetrazole;

I-127: 5-{3-[3-(3-methyl-3-tetrazol-5-yl-butoxy)-propoxy]-1,1-dimethyl-propyl}-(1*H*)-tetrazole;

I-128: 5-{3-[3-(3-methyl-3-(3-methyl-isoxazol-5-yl)-butoxy)-propoxy]-1,1-dimethyl-propyl}-3-methyl-isoxazole;

I-129: 4-{3-[3-(3-methyl-3-(3-methyl-isoxazol-4-yl)-butoxy)-propoxy]-1,1-dimethyl-propyl}-3-methyl-isoxazole;

I-130: 3-{3-[3-(3-methyl-3-(5-hydroxy-pyran-3-yl-4-one)-butoxy)-propoxy]-1,1-dimethyl-propyl}-5-hydroxy-pyran-4-one;

I-131: 2-{3-[3-(3-methyl-3-(5-hydroxy-pyran-2-yl-4-one)-butoxy)-propoxy]-1,1-dimethyl-propyl}-5-hydroxy-pyran-4-one;

I-132: 3-{3-[3-(3-methyl-3-(5-hydroxy-pyran-2-yl-4-one)-butoxy)-propoxy]-1,1-dimethyl-propyl}-5-hydroxy-pyran-4-one;

I-133: 1-ethyl-3-(3-{3-[3-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3-methyl-butoxy]-propoxy}-1,1-dimethyl-propyl)-imidazolidine-2,4-dithione;

I-134: 1-ethyl-3-(3-{3-[3-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3-methyl-butoxy]-propoxy}-1,1-dimethyl-propyl)-imidazolidine-2,4-dithione;

I-135: 1-ethyl-3-(3-{3-[3-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3-methyl-butoxy]-propoxy}-1,1-dimethyl-propyl)-imidazolidine-2,4-dione;

I-136: 1-ethyl-3-(3-{3-[3-(3-ethyl-2-thioxo-5-oxo-imidazolidin-1-yl)-3-methyl-butoxy]-propoxy}-1,1-dimethyl-propyl)-imidazolidine-2-thioxo-4-one;

I-137: 1-ethyl-3-(3-{3-[3-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-3-methyl-butoxy]-propoxy}-1,1-dimethyl-propyl)-imidazolidine-2-oxo-4-thione;

I-138: 1-(2-tetrahydropyranyloxy)-2-{2-[2-(2-tetrahydropyranyloxy)-ethoxy]-propoxy}ethane;

I-139: 4-{2-[3-(oxetan-4-yl-2-one)-propoxy-propoxy]-ethyl}-oxetan-2-one;

I-140: 3-{2-[3-(oxetan-3-yl--2-one)-propoxy-propoxy]-ethyl}-oxetan-2-one;

I-141: 5-{2-[3-(dihydro-furan-5-yl-2-one)-propoxy-propoxy]-ethyl}-dihydro-furan-2-one;

I-142: 4-{2-[3-(dihydro-furan-4-yl-2-one)-propoxy-propoxy]-ethyl}-dihydro-furan-2-one;

I-143: 3-{2-[3-(dihydro-furan-3-yl-2-one)-propoxy-propoxy]-ethyl}-dihydro-furan-2-one;

I-144: [2-(2-{3-[2-(4-carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethoxy]-propoxy}-ethyl)-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl]-acetic acid;

I-145: 2,2'-[propylenebis(oxadiyl)]diethane-6-d-valerolactone;

I-146: 2,2'-[propylenebis(oxadiyl)]diethane-5-d-valerolactone;

I-147: 2,2'-[propylenebis(oxadiyl)]diethane-4-d-valerolactone;

I-148: 2,2'-[propylenebis(oxadiyl)]diethane-3-d-valerolactone;

I-149: 5-[3-(5-hydroxy-3,3-dimethyl-pentyloxy)-propoxy]-3,3-dimethyl-pentan-1-ol;

I-150: 5-[3-(4-carboxy-3,3-dimethyl-butoxy)-propoxy]-3,3-dimethyl-pentanoic acid;

I-151: 5-[3-(3,3-dimethyl-5-oxo-pentyloxy)-propoxy]-3,3-dimethyl-pentanal;

I-152: 5-[3-(4-methoxycarbonyl-3,3-dimethyl-butoxy)-propoxy]-3,3-dimethyl-pentanoic acid methyl ester;

I-153: 5-[3-(3,3-dimethyl-4-phenoxycarbonyl-butoxy)-propoxy]-3,3-dimethyl-pentanoic acid phenyl ester;

I-154: 5-[3-(4-benzyloxycarbonyl-3,3-dimethyl-butoxy)-propoxy]-3,3-dimethyl-pentanoic acid benzyl ester;

I-155: 4-[3-(3,3-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl-butane-1-sulfonic acid;

I-156: phosphoric acid mono-{4-[3-(3,3-dimethyl-4-phosphonooxy-butoxy)-propoxy]-2,2-dimethyl-butyl}ester;

I-157: 5-{4-[3-(3,3-dimethyl-4-(5-(3,3a-dihydro-2*H*-thieno-[3,2-c]pyridine-4,6-dioxo) pentyloxy)-propoxy]-2,2-dimethyl-butyl}- 3,3a-dihydro3,3a-dihydro-2*H*-thieno-[3,2-c]pyridine-4,6-dione;

I-158: 5-{4-[3-(3,3-dimethyl-4-(5-(3,3a-dihydro-2*H*-thieno-[3,2-c]pyridine-4,6-dithioxo)pentyloxy)-propoxy]-2,2-dimethyl-butyl}- 3,3a-dihydro-3,3a-dihydro-2*H*-thieno-[3,2-c]pyridine-4,6-dithione;

I-159: 5-[3-(3,3-dimethyl-4-cyano-carbamoyl-butoxy)-propoxy]-3,3-dimethyl-n-cyano- pentanoic acid-amide;

I-160: phosphoramidic acid mono-(5-{2-[4-(amino-hydroxy-phosphoryloxy)- 3,3-dimethyl-butoxy]-ethoxy}-2,2-dimethyl-pentyl) ester;

I-161: {4-[3-(3,3-dimethyl-4-phosponamido-butoxy)-propoxy]-2,2-dimethyl-butyl}-phosphonamide;

I-162: 1-{4-[3-(3,3-dimethyl-5-(1*H*-tetrazol-1-yl)-butoxy)-propoxy]-2,2-dimethyl-butyl}-1*H*-tetrazole;

I-163: 5-{4-[3-(3,3-dimethyl-5-(1*H*-tetrazol-5-yl)-butoxy)-propoxy]-2,2-dimethyl-butyl}-1*H*-tetrazole;

I-164: 5-{4-[3-(3,3-dimethyl-5-(3-hydroxy-isoxazol-5-yl)-butoxy)-propoxy]-2,2-dimethyl-butyl}-3-hydroxy-isoxazole;

I-165: 4-{4-[3-(3,3-dimethyl-5-(3-hydroxy-isoxazol-4-yl)-butoxy)-propoxy]-2,2-dimethyl-butyl}-3-hydroxy-isoxazole;

I-166: 2-{4-[3-(3,3-dimethyl-4-{5-hydroxy-pyran-4-oxo-3-yl}-butyloxy)-propoxy]-2,2- dimethyl-butyl}-5-hydroxy-pyran-4-one;

I-167: 2-{4-[3-(3,3-dimethyl-4-{5-hydroxy-pyran-4-oxo-2-yl}-butyloxy)-propoxy]-2,2- dimethyl-butyl}-5-hydroxy-pyran-4-one;

I-168: 3-{4-[3-(3,3-dimethyl-4-{5-hydroxy-pyran-4-oxo-3-yl}-butyloxy)-propoxy]-2,2-dimethyl-butyl}-5-hydroxy-pyran-4-one;

I-169: 1-ethyl-3-(4-{3-[4-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3-dimethyl-butoxy]-propoxy}-2,2-dimethyl-butyl)-imidazolidine- 2,4-dione;

I-170: 1-ethyl-3-(4-{3-[4-(3-ethyl-2,5-oxo-imidazolidin-1-yl)-3,3-dimethyl-butoxy]-propoxy}-2,2-dimethyl-butyl)-imidazolidine-2,4-dione;

I-171: 1-ethyl-3-(4-{3-[4-(3-ethyl-2-thioxo-5-oxo-imidazolidin-1-yl)-3,3-dimethyl-butoxy]-propoxy}-2,2-dimethyl-butyl)-imidazolidine-2-thioxo-4-one;

I-172: 1-ethyl-3-(4-{3-[4-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-3,3-dimethyl-butoxy]-propoxy}-2,2-dimethyl-butyl)-imidazolidine-2-oxo-4-thione;

I-173: 5-[3-(4-hydroxy-4-methyl-pentyloxy)-propoxy]-2-methyl-pentan-2-ol;

I-174: 5-[3-(5-hydroxy-4,4-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl-pentan-1-ol;

I-175: 5-[3-(4-carboxy-4-methyl-pentyloxy)-propoxy]-2,2-dimethyl-pentanoic acid;

I-176: 5-[3-(4,4-dimethyl-5-oxo-pentyloxy)-propoxy]-2,2-dimethyl-pentanal;

I-177: 5-[3-(4-methoxycarbonyl-4-methyl-pentyloxy)-propoxy]-2,2-dimethyl-pentanoic acid methyl ester;

I-178: 5-[3-(4,4-dimethyl-5-oxo-6-phenyl-hexyloxy)-propoxy]-2,2-dimethyl-pentanoic acid phenyl ester;

I-179: 4-{3-[1-(2-benzyloxycarbonyl-2-methyl-propyl)-vinyloxy]-propoxy}- 2,2-dimethyl- pent-4-enoic acid benzyl ester;

I-180: 2-methyl-5-[3-(4-methyl-4-sulfo-pentyloxy)-propoxy]-pentane-2-sulfonic acid;

I-181: phosphoric acid mono-{1,1-dimethyl-4-[3-(4-methyl-4-phosphonooxy-pentyloxy)-propoxy]-butyl}ester;

I-182: 5-(5-{3-[3,3-dimethyl-5-(4,6-dioxo-2,3,3a,6-tetrahydro-4h-thieno-[3,2-c]pyridin-5-yl)-pentyloxy]-propoxy}-3,3-dimethyl-pentyl)-3,3a- dihydro-2*H*-thieno[3,2-c]pyridine-4,6-dione;

I-183: 5-(5-{3-[3,3-dimethyl-5-(4,6-dithioxo-2,3,3a,6-tetrahydro-4h-thieno-[3,2-c]pyridin-5-yl)-pentyloxy]-propoxy}-3,3-dimethyl-pentyl)-3,3a-dihydro-2*H*-thieno[3,2-c]pyridine-4,6-dithione;

I-184: 5-{3-[4-*N*-cyano-carbamoyl-4-methyl-pentyloxy)-propoxy]-2,2-dimethyl-*N*-cyano-pentanoic acid-amide;

I-185: phosphoramidic acid mono-[3-(3-{1-[2-(amino-hydroxy- phosphoryloxy)-2-methyl-propyl]-vinyloxy}-propoxy)-1,1-dimethyl-but-3-enyl] ester;

I-186: {1,1-dimethyl-4-[3-(4-methyl-4-phosphonamido-pentyloxy)-propoxy]-butyl}-phosphonamide;

I-187: 1-{4-[3-(4-{1*H*-tetrazol-1-yl}-4-methyl-pentyloxy)-propoxy]-1,1-dimethyl-butyl}-1*H*-tetrazol;

I-188: 5-{4-[3-(4-{1*H*-tetrazol-5-yl}-4-methyl-pentyloxy)-propoxy]-1,1-dimethyl-butyl}-1*H*-tetrazole;

I-189: 5-{4-[3-(4-{3-methyl-isoxazol-5-yl}-4-methyl-pentyloxy)-propoxy]-1,1-dimethyl-butyl}-3-methyl-isoxazole;

I-190: 4-{4-[3-(4-{3-methyl-isoxazol-4-yl}-4-methyl-pentyloxy)-propoxy]-1,1-dimethyl-butyl}-3-methyl-isoxazole;

I-191: 3-{4-[3-(4-{5-hydroxy-4-oxo-pyran-3-yl}-4-methyl-pentyloxy)-propoxy]-1,1- dimethyl-butyl}-5-hydroxy-pyran-4-one;

I-192: 2-{4-[3-(4-{5-hydroxy-4-oxo-pyran-2-yl}-4-methyl-pentyloxy)-propoxy]-1,1- dimethyl-butyl}-5-hydroxy-pyran-4-one;

I-193: 1-ethyl-3-(4-{3-[4-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-4-methyl-pentyloxy]- propoxy}-1,1-dimethyl-butyl)-imidazolidine-2,4-dione;

I-194: 1-ethyl-3-(4-{3-[4-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-4-methyl-pentyloxy]-propoxy}-1,1-dimethyl-butyl)-imidazolidine-2,4-dione;

I-195: 1-ethyl-3-(4-{3-[4-(3-ethyl-5-oxo-2-thioxo-imidazolidin- 1-yl)-4-methyl-pentyloxy]-propoxy}-1,1-dimethyl-butyl)-imidazolidine-4-oxo-2-thione;

I-196: 1-ethyl-3-(4-{3-[4-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-4-methyl-pentyloxy]-propoxy}-1,1-dimethyl-butyl)-imidazolidine-2-oxo-4-thione;

I-197: 2-{3-[3-(3-{tetrahydro-pyran-2-yl}-propoxy)-propoxy]-propoxy}-tetrahydro-pyran;

I-198: 4-{3-[3-(3-{oxetan-2-one-4-yl}propoxy)-propoxy]-propyl}-oxetan-2-one;

I-199: 3-{3-[3-(3-{oxetan-2-one-3-yl}propoxy)-propoxy]-propyl}-oxetan-2-one;

I-200: 5-{3-[3-(3-{dihydro-furan-2-one-5-yl}-propoxy)-propoxy]-propyl}-dihydro-furan-2-one;

I-201: 4-{3-[3-(3-{dihydro-furan-2-one-4-yl}-propoxy)-propoxy]-propyl}-dihydro-furan-2-one;

I-202: 3-{3-[3-(3-{dihydro-furan-2-one-3-yl}-propoxy)-propoxy]-propyl}-dihydro-furan-2-one;

I-203: {2-[3-(3-{3-[4-carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-propoxy}-propoxy)-propyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid;

I-204: 6-{3-[3-(3-{dihydro-pyran-2-one-6-yl}-propoxy)-propoxy]-propyl}-dihydro-pyran-2-one;

I-205: 5-{3-[3-(3-{dihydro-pyran-2-one-5-yl}-propoxy)-propoxy]-propyl}-dihydro-pyran-2-one;

I-206: 4-{3-[3-(3-{dihydro-pyran-2-one-4-yl}-propoxy)-propoxy]-propyl}-dihydro-pyran-2-one;

I-207: 3-{3-[3-(3-{dihydro-pyran-2-one-3-yl}-propoxy)-propoxy]-propyl}-dihydro-pyran-2-one;

I-208: 6-[3-(6-hydroxy-4,4-dimethyl-hexyloxy)-propoxy]-3,3-dimethyl-hexan-1-ol;

I-209: 6-[3-(5-carboxy-4,4-dimethyl-pentyloxy)-propoxy]-3,3-dimethyl-hexanoic acid;

I-210: 6-[3-(4,4-dimethyl-6-oxo-hexyloxy)-propoxy]-3,3-dimethyl-hexanal;

I-211: 6-[3-(5-methoxycarbonyl-4,4-dimethyl-pentyloxy)-propoxy]-3,3-dimethyl-hexanoic acid methyl ester;

I-212: 6-[3-(4,4-dimethyl-5-phenoxycarbonyl-pentyloxy)-propoxy]-3,3-dimethyl-hexanoic acid cyclohexyl ester;

I-213: 6-[3-(5-benzyloxycarbonyl-4,4-dimethyl-pentyloxy)-propoxy]-3,3-dimethyl-hexanoic acid benzyl ester;

I-214: 5-[3-(4,4-dimethyl-5-sulfo-pentyloxy)-propoxy]-2,2- dimethyl-pentane-1-sulfonic acid;

I-215: 5-[3-(4,4-dimethyl-5-phospo-pentyloxy)-propoxy]-2,2-dimethyl-pentane-1-phosphonic acid;

I-216: 5-{5-[3-(5-{3,3a-dihydro-2*H*-thieno[3,2-c]pyridine-4,6-dione-5-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl-3-pentyl}-3,3a-dihydro-2*H*-thieno[3,2-c]pyridine-4,6-dione;

I-217: 5-{5-[3-(5-{3,3a-dihydro-2*H*-thieno[3,2-c]pyridine-4,6-dithione-5-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl-3-pentyl}-3,3a-dihydro-2*H*-thieno[3,2-c]pyridine-4,6-dithione;

I-218: 6-[3-(5-cyano-carbamoyl-4,4-dimethyl-pentyloxy)-propoxy]-3,3-dimethyl-N-cyano-hexanoic acid-amide;

I-219: phosphoramidic acid mono-(6-{2-[5-(amino-hydroxy-phosphoryloxy)- 4,4-dimethyl- pentyloxy]-ethoxy}-2,2-dimethyl-hexyl) ester;

I-220: {5-[3-(4,4-dimethyl-5-phosphonamido-pentyloxy)-propoxy]-2,2-dimethyl-pentyl}-phosphonamide;

I-221: 1-{5-[3-(5-{1*H*-tetrazol-1-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl- pentyl}-1*H*-tetrazole;

I-222: 5-{5-[3-(5-{1*H*-tetrazol-5-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl- pentyl}-1*H*-tetrazole;

I-223: 5-{5-[3-(5-{3-hydroxy-isoxazol-5-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2- dimethyl-pentyl}-3-hydroxy-isoxazole;

I-224: 4-{5-[3-(5-{3-hydroxy-isoxazol-4-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2- dimethyl-pentyl}-3-hydroxy-isoxazole;

I-225: 2-{5-[3-(5-{5-hydroxy-4-oxo-pyran-3-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl-pentyl}-5-hydroxy-pyran-4-one;

I-226: 2-{5-[3-(5-{5-hydroxy-4-oxo-pyran-2-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2- dimethyl-pentyl}-5-hydroxy-pyran-4-one;

I-227: 3-{5-[3-(5-{5-hydroxy-4-oxo-pyran-3-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2- dimethyl-pentyl}-5-hydroxy-pyran-4-one;

I-228: 3-{4-[3-(5-{3-ethyl-2,5-dithioxo-imidazolidin-1-yl}-4,4-dimethyl-pentyloxy)- propoxy]-2,2-dimethyl-butyl}-1-ethyl-imidazolidine-2,4-dithione;

I-229: 3-{4-[3-(5-{3-ethyl-2,5-dioxo-imidazolidin-1-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl-butyl}-1-ethyl-imidazolidine-2,4-dione;

I-230: 3-{4-[3-(5-{3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl}-4,4-dimethyl-pentyloxy)- propoxy]-2,2-dimethyl-butyl}-1-ethyl-imidazolidine-4-oxo-2-thione;

I-231: 3-{4-[3-(5-{3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl}-4,4-dimethyl-pentyloxy)-propoxy]-2,2-dimethyl-butyl}-1-ethyl-imidazolidine-2-oxo-4-thione;

I-232: 6-[3-(5-hydroxy-5-methyl-hexyloxy)-propoxy]-2-methyl-hexan-2-ol;

I-233: 6-[3-(6-hydroxy-5,5-dimethyl-hexyloxy)-propoxy]-2,2-dimethyl-hexan-1-ol;

I-234: 6-[3-(5-carboxy-5-methyl-hexyloxy)-propoxy]-2,2-dimethyl-hexanoic acid;

I-235: 6-[3-(5,5-dimethyl-6-oxo-hexyloxy)-propoxy]-2,2-dimethyl-hexanal;

I-236: 6-[3-(5-methoxycarbonyl-5-methyl-hexyloxy)-propoxy]-2,2-dimethyl-hexanoic acid methyl ester;

I-237: 6-[3-(5,5-dimethyl-6-oxo-7-phenyl-heptyloxy)-propoxy]-2,2-dimethyl-hexanoic acid phenyl ester;

I-238: 6-[3-(5-benzyloxycarbonyl-5-methyl-hexyloxy)-propoxy]-2,2-dimethyl-hexanoic acid benzyl ester;

I-239: 2-methyl-6-[3-(5-methyl-5-sulfo-hexyloxy)-propoxy]-hexane-2-sulfonic acid;

I-240: phosphoric acid mono-{1,1-dimethyl-5-[3-(5-methyl-5-phosphonooxy-hexyloxy)-propoxy]- pentyl} ester;

I-241: 5-(5-{3-[4-(4,6-dioxo-hexahydro-thieno[3,2-c]pyridin-5-yl)-4- methyl-pentyloxy]-propoxy}-1,1-dimethyl-pentyl)-3,3a-dihydro-2*H*-thieno-[3,2-c] pyridine-4,6- dione;

I-242: 5-(5-{3-[4-(4,6-dithioxo-hexahydro-thieno[3,2-c]pyridin-5-yl)-4-methyl-pentyloxy]-propoxy}-1,1-dimethyl-pentyl)-3,3a-dihydro-2*H*-thieno[3,2-c]pyridine-4,6- dithione;

I-243: 6-[3-(4-*N*-cyano-carbamoyl-4-methyl-pentyloxy)-propoxy]-2,2-dimethyl-*N*-cyano- hexanoic acid-amide;

I-244: phosphoramidic acid mono-(5-{3-[5- (amino-hydroxy-phosphoryloxy)- 5-methyl-hexyloxy]-propoxy}- 1,1-dimethyl-pentyl) ester;

I-245: {1,1-dimethyl-5-[3-(5-methyl-5-phosphonamido-hexyloxy)- propoxy]-pentyl}-phosphonamide;

I-246: 1-{5-[3-(5-{1*H*-tetrazol-1-yl}-5-methyl-hexyloxy)-propoxy]-1,1-dimethyl-pentyl}-1*H*-tetrazole;

I-247: 5-{5-[3-(5-{1*H*-tetrazol-5-yl}-5-methyl-hexyloxy)-propoxy]-1,1-dimethyl-pentyl}-1*H*-tetrazole;

I-248: 5-{5-[3-(5-{3-hydroxy-isoxazol-5-yl}-5-methyl-hexyloxy)-propoxy]-1,1-dimethyl-pentyl}-3-hydroxy-isoxazole;

I-249: 4-{5-[3-(5-{3-hydroxy-isoxazol-4yl}-5-methyl-hexyloxy)-propoxy]-1,1-dimethyl-pentyl}-3-hydroxy-isoxazole;

I-250: 3-{5-[3-(5-{5-hydroxy-4-oxo-pyran-3-yl}-5-methyl-hexyloxy)-propoxy]-1,1- dimethyl-pentyl}-5-hydroxy-pyran-4-one;

I-251: 2-{5-[3-(5-{5-hydroxy-4-oxo-pyran-2-yl}-5-methyl-hexyloxy)-propoxy]-1,1- dimethyl-pentyl}-5-hydroxy-pyran-4-one;

I-252: 1-ethyl-3-(5-{3-[5-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-5-methyl-hexyloxy]-propoxy}-2,2-dimethyl-hexyl)-imidazolidine-2,4-dione;

I-253: 1-ethyl-3-(5-{3-[5-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-5-methyl-hexyloxy]-propoxy}-2,2-dimethyl-hexyl)-imidazolidine-2,4-dione;

I-254: 1-ethyl-3-(5-{3-[5-(3-ethyl-2-thioxo-5-oxo-imidazolidin-1-yl)-5-methyl-hexyloxy]- propoxy}-2,2-dimethyl-hexyl)-imidazolidine-4-oxo-2-thione;

I-255: 1-ethyl-3-(5-{3-[5-(3-ethyl-5-thioxo-2-oxo-imidazolidin-1-yl)-5-methyl-hexyloxy]- propoxy}-2,2-dimethyl-hexyl)-imidazolidine- 2-oxo-4-thione;

I-256: 2-{4-[3-(4-{tetrahydro-pyran-2-yl}-butoxy)-propoxy]-butoxy}-tetrahydro-pyran;

I-257: 4-{4-[3-(4-{oxetan-2-one-4-yl}-butoxy)-propoxy]-butyl}-oxetan-2-one;

I-258: 3-{4-[3-(4-{oxetan-2-one-3-yl}-butoxy)-propoxy]-butyl}-oxetan-2-one;

I-259: 5-{4-[3-(4-{tetrahydro-furan-2-one-5-yl}-butoxy)-propoxy]-butyl}-tetrahydro-furan-2-one;

I-260: 4-{4-[3-(4-{tetrahydro-furan-2-one-4-yl}-butoxy)-propoxy]-butyl}-tetrahydro-furan-2-one;

I-261: 3-{4-[3-(4-{tetrahydro-furan-2-one-3-yl}-butoxy)-propoxy]-butyl}-tetrahydro-furan-2-one;

I-262: [2-(4-{3-[4-(4-carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-butoxy]- propoxy}-butyl)-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl)-acetic acid;

I-263: 6-{4-[3-(4-{tetrahydro-pyran-2-one-6-yl}-butoxy)-propoxy]-butyl}-tetrahydro- pyran-2-one;

I-264: 5-{4-[3-(4-{tetrahydro-pyran-2-one-5-yl}-butoxy)-propoxy]-butyl}-tetrahydro-pyran-2-one;

I-265: 4-{4-[3-(4-{tetrahydro-pyran-2-one-4-yl}-butoxy)-propoxy]-butyl}-tetrahydro-pyran-2-one;

I-266: 3-{4-[3-(4-{tetrahydro-pyran-2-one-3-yl}-butoxy)-propoxy]-butyl}-tetrahydro-pyran-2-one;

I-267: 7-[3-(7-hydroxy-5,5-dimethyl-heptyloxy)-propoxy]-3,3-dimethyl-heptan-1-ol;

I-268: 7-[3-(6-carboxy-5,5-dimethyl-hexyloxy)-propoxy]-3,3-dimethyl-heptanoic acid;

I-269: 7-[3-(5,5-dimethyl-6-oxo-hexyloxy)-propoxy]-3,3-dimethyl-heptanal;

I-270: 7-[3-(6-methoxycarbonyl-5,5-dimethyl-hexyloxy)-propoxy]-3,3-dimethyl-heptanoic acid methyl ester;

I-271: 7-[3-(5,5-dimethyl-6-phenoxycarbonyl-hexyloxy)-propoxy]-3,3-dimethyl-heptanoic acid phenyl ester;

I-272: 7-[3-(6-benzyloxycarbonyl-5,5-dimethyl-hexyloxy)-propoxy]-3,3-dimethyl-heptanoic acid benzyl ester;

I-273: 6-[3-(5,5-dimethyl-6-sulfo-hexyloxy)-propoxy]-2,2-dimethyl-hexane-1-sulfonic acid;

I-274: phosphoric acid mono-{6-[3-(5,5-dimethyl-6-phosphonooxy-hexyloxy)-propoxy]-2,2-dimethyl-hexyl}-ester;

I-275: 5-(6-{3-[6-(4,6-dioxo-hexahydro-thieno[3,2-c]pyridin-5-yl)-5,5-dimethyl-hexyloxy]-propoxy}-2,2-dimethyl-hexyl)-3,3a-dihydro-2*H*- thieno[3,2-c] pyridine-4,6-dione;

I-276: 5-(5-{3-[4-(4,6-dithioxo-hexahydro-thieno[3,2-c]pyridin-5-yl)-4-methyl-pentyloxy]-propoxy}-1,1-dimethyl-pentyl)- 3,3a- dihydro-2*H*- thieno [3,2-c] pyridine-4,6-dithione;

I-277: 7-[3-(6-*N*-cyano-carbamoyl-5,5-dimethyl-hexyloxy)-propoxy]-3,3-dimethyl-*N*-cyano-heptanoic acid-amide;

I-278: phosphoramidic acid mono-{7-[2-(6-{amino-hydroxy-phosphoryloxy}-5,5-dimethyl-hexyloxy)-ethoxy]-2,2-dimethyl-heptyl}ester;

I-279: {6-[3-(5,5-dimethyl-6-phosphonamido-hexyloxy)-propoxy]-2,2,-dimethyl-hexyl}-phosphonamide;

I-280: 1-{6-[3-(6-{1*H*-tetrazol-1-yl}-5,5-dimethyl-hexyloxy)-propoxy]-2,2-dimethyl-hexyl}-1*H*-tetrazole;

I-281: 5-{6-[3-(6-{1*H*-tetrazol-5-yl}-5,5-dimethyl-hexyloxy)-propoxy]-2,2-dimethyl-hexyl}-1*H*-tetrazole;

I-282: 5-{6-[3-(6-{3-hydroxy-isoxazol-5-yl}-5,5-dimethyl-hexyloxy)-propoxy]-2,2- dimethyl-hexyl}-3-hydroxy-isoxazole;

I-283: 4-{6-[3-(6-{3-hydroxy-isoxazol-4-yl}-5,5-dimethyl-hexyloxy)-propoxy]-2,2- dimethyl-hexyl}-3-hydroxy-isoxazole;

I-284: 2-{6-[3-(6-{5-hydroxy-4-oxo-pyran-3-yl}-5,5-dimethyl-hexyloxy)-propoxy]-2,2- dimethyl-hexyl}-5-hydroxy-pyran-4-one;

I-285: 2-{6-[3-(6-{5-hydroxy-4-oxo-pyran-2-yl}-5,5-dimethyl-hexyloxy)-propoxy]-2,2- dimethyl-hexyl}-5-hydroxy-pyran-4-one;

I-286: 3-{6-[3-(6-{5-hydroxy-4-oxo-pyran-3-yl}-5,5-dimethyl-hexyloxy)-propoxy]-2,2- dimethyl-hexyl}-5-hydroxy-pyran-4-one;

I-287: 1-ethyl-3-(6-{3-[6-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-5,5-dimethyl-hexyloxy]- propoxy}-2,2-dimethyl-hexyl)- imidazolidine- 2,4-dione;

I-288: 1-ethyl-3-(6-{3-[6-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-5,5-dimethyl-hexyloxy]-propoxy}-2,2-dimethyl-hexyl)-imidazolidine-2,4-dione;

I-289: 1-ethyl-3-(6-{3-[6-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-5,5- dimethyl-hexyloxy]-propoxy}-2,2- dimethyl-hexyl)- imidazolidine-4-oxo-2-thione;

I-290: 1-ethyl-3-(6-{3-[6-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)- 5,5-dimethyl-hexyloxy]-propoxy}-2,2-dimethyl-hexyl)-imidazolidine-2-oxo-4-thione;

I-291: 6-[3-(5-carboxy-5-methyl-hexyloxymethyl)-benzyloxy]-2,2-dimethyl-hexanoic acid;

I-292: 6-[3-(5-carboxy-5-methyl-hexyloxymethyl)-benzyloxy]-2,2-dimethyl-hexan-1-ol;

I-293: 6-[3-(6-hydroxy-5,5-dimethyl-hexyloxymethyl)-benzyloxy]-2,2-dimethyl-hexan-1-ol;

I-294: 5-[3-(4-carboxy-4-methyl-pentyloxymethyl)-benzyloxy]-2,2-dimethyl-pentanoic acid;

I-295: 5-[3-(4-carboxy-4-methyl-pentyloxymethyl)-benzyloxy]-2,2-dimethyl-hexan-1-ol;

I-296: 5-[3-(5-hydroxy-4,4-dimethyl-pentyloxymethyl)-benzyloxy]-2,2-dimethyl-pentan-1-ol; or

I-297: 5-[2-(5-hydroxy-4,4-dimethyl-pentyloxy)-ethoxy]-2,2-dimethyl-pentan-1-ol.

30. A compound of the formula **II**:



II

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

(a) each occurrence of Z is independently $(CH_2)_m$, $(CH{=}CH)_t$, or phenyl, where each occurrence of m and t are independent integers ranging from 1 to 5;

(b) G is $(CH_2)_x$, $CH_2CH{=}CHCH_2$, CH=CH, CH_2-phenyl-CH_2, or phenyl, where x is an integer ranging from 1 to 4;

(c) W^1 and W^2 are independently $C(R^1)(R^2)(CH_2)_n$-Y, V, or $C(R^1)(R^2)$-$(CH_2)_c$-V where c is 1 or 2 and n is an integer ranging from 0 to 4;

(d) each occurrence of R^1 and R^2 is independently $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, phenyl, or benzyl;

(e) V is



(f) each occurrence of Y is independently OH, COOH, CHO, $COOR^7$, SO_3H,





(g) R^7 is $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1$-$C_6)$alkoxy, or phenyl groups;

(h) each occurrence of R^8 is independently H, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $(C_1$-$C_6)$alkoxy, or phenyl groups;

(i) each occurrence of R^9 is independently H, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl; and

(j) each occurrence of p is independently 0 or 1 where the broken line represents an optional presence of 1 or 2 additional carbon-carbon bonds that when present complete 1 or 2 carbon-carbon double bonds.

31. The compound of claim 30, wherein W^1 and W^2 are independent $C(R^1)(R^2)(CH_2)_n$-Y groups and each occurrence of Y is independently OH, $COOR^7$, or COOH.

32. The compound of claim 30, wherein W^1 is $C(R^1)(R^2)(CH_2)_n$-Y.

33. The compound of claim 30, wherein W^1 is V.

34. The compound of claim 30, wherein W^1 is $C(R^1)(R^2)$-$(CH_2)_c$-V.

35. The compound of claim 30, wherein p is 0.

36. The compound of claim 30, wherein p is 1.

37. The compound of claim 30, wherein t is 1.

38. A compound of the formula **IIa**:



IIa

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

(a) each occurrence of m is independently an integer ranging from 1 to 5;

(b) x is an integer ranging from 1 to 4;

(c) W^1 and W^2 are independently $C(R^1)(R^2)(CH_2)_{n-}Y$, V, or $C(R^1)(R^2)-(CH_2)_{c-}V$ where c is 1 or 2 and n is an integer ranging from 0 to 4;

(d) each occurrence of R^1 and R^2 is independently (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, phenyl, or benzyl;

(e) V is



(f) Y is OH, COOH, CHO, $COOR^7$, SO_3H,



(g) R^7 is $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1\text{-}C_6)$alkoxy, or phenyl groups;

(h) each occurrence of R^8 is independently H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, or $(C_2\text{-}C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $(C_1\text{-}C_6)$alkoxy, or phenyl groups;

(i) each occurrence of R^9 is independently H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, or $(C_2\text{-}C_6)$alkynyl; and

(j) each occurrence of p is independently 0 or 1.

39. The compound of claim 38, wherein W^1 and W^2 are independent $C(R^1)(R^2)(CH_2)_n$–Y groups and each occurrence of Y is independently OH, $COOR^7$, or COOH.

40. The compound of claim 38, wherein W^1 is $C(R^1)(R^2)(CH_2)_n$–Y.

41. The compound of claim 38, wherein W^1 is V.

42. The compound of claim 38, wherein W^1 is $C(R^1)(R^2)$–$(CH_2)_c$–V.

43. The compound of claim 38, wherein p is 0.

44. The compound of claim 38, wherein p is 1.

45. A compound of the formula:

II-1: 5-(6-{3-[6-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-propyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-2: 5-(6-{3-[6-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-propyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-3: 5-(6-{3-[6-(4-carboxyl-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-propyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-4: 5-(6-{3-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-propyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-5: 5-(6-{3-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-propyl-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-6: 5-(6-{3-[6-(4-carboxyl-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-propyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-7: 6-(6-{3-[6-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-propyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexan-1-ol;

II-8: 6-(6-{3-[6-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-propyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-9: 6-(6-{3-[6-(5-carboxyl-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-propyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-10: 6-(6-{3-[6-(6-hydroxy-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-propyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexan-1-ol;

II-11: 6-(6-{3-[6-(6-hydroxy-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-propyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-12: 6-(6-{3-[6-(5-carboxyl-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-propyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-13: 6-(6-{2-[6-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-vinyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexan-1-ol;

II-14: 6-(6-{2-[6-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-vinyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-15: 6-(6-{2-[6-(5-carboxyl-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-vinyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-16: 6-(6-{2-[6-(6-hydroxy-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-vinyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexan-1-ol;

II-17: 6-(6-{2-[6-(6-hydroxy-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-vinyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-18: 6-(6-{2-[6-(5-carboxyl-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-vinyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-19: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-vinyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-20: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-vinyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-21: 5-(6-{2-[6-(4-carboxyl-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-vinyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-22: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-vinyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-23: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-vinyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-24: 5-(6-{2-[6-(4-carboxyl-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-vinyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-25: 6-(6-{2-[6-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-phenyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexan-1-ol;

II-26: 6-(6-{2-[6-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-phenyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-27: 6-(6-{2-[6-(5-carboxyl-5,5-dimethyl-hexyl)-tetrahydro-pyran-2-yl]-phenyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-28: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-phenyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-29: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-phenyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-30: 5-(6-{2-[6-(4-carboxyl-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-phenyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-31: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-phenyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-32: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-phenyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-33: 5-(6-{2-[6-(4-carboxyl-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-phenyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-34: 6-(6-{2-[6-(6-hydroxy-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-phenyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexan-1-ol;

II-35: 6-(6-{2-[6-(6-hydroxy-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-phenyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-36: 6-(6-{2-[6-(5-carboxyl-5,5-dimethyl-hexyl)-4-oxo-pyran-2-yl]-phenyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-hexanoic acid;

II-37: 5-(5-{3-[5-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-propyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentan-1-ol;

II-38: 5-(5-{3-[5-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-propyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-39: 5-(5-{3-[5-(4-carboxyl-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-propyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-40: 5-(5-{3-[5-(5-hydroxy-4,4-dimethyl-pentyl)-furan-2-yl]-propyl}-furan-2-yl)-2,2-dimethyl-pentan-1-ol;

II-41: 5-(5-{3-[5-(5-hydroxy-4,4-dimethyl-pentyl)-furan-2-yl]-propyl}-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-42: 5-(5-{3-[5-(4-carboxyl-4,4-dimethyl-pentyl)-furan-2-yl]-propyl}-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-43: 6-(5-{3-[5-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-propyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexan-1-ol;

II-44: 6-(5-{3-[5-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-propyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-45: 6-(5-{3-[5-(5-carboxyl-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-propyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-46: 6-(5-{3-[5-(6-hydroxy-5,5-dimethyl-hexyl)-furan-2-yl]-propyl}-furan-2-yl)-2,2-dimethyl-hexan-1-ol;

II-47: 6-(5-{3-[5-(6-hydroxy-5,5-dimethyl-hexyl)-furan-2-yl]-propyl}-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-48: 6-(5-{3-[5-(5-carboxyl-5,5-dimethyl-hexyl)-furan-2-yl]-propyl}-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-49: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-vinyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexan-1-ol;

II-50: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-vinyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-51: 6-(5-{2-[5-(5-carboxyl-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-vinyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-52: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-furan-2-yl]-vinyl}-furan-2-yl)-2,2-dimethyl-hexan-1-ol;

II-53: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-furan-2-yl]-vinyl}-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-54: 6-(5-{2-[5-(5-carboxyl-5,5-dimethyl-hexyl)-furan-2-yl]-vinyl}-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-55: 5-(5-{2-[5-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-vinyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentan-1-ol;

II-56: 5-(5-{2-[5-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-vinyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-57: 5-(5-{2-[5-(4-carboxyl-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-vinyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-58: 5-(5-{2-[5-(5-hydroxy-4,4-dimethyl-pentyl)-furan-2-yl]-vinyl}-furan-2-yl)-2,2-dimethyl-pentan-1-ol;

II-59: 5-(5-{2-[5-(5-hydroxy-4,4-dimethyl-pentyl)-furan-2-yl]-vinyl}-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-60: 5-(5-{2-[5-(4-carboxyl-4,4-dimethyl-pentyl)-furan-2-yl]-vinyl}-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-61: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-phenyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexan-1-ol;

II-62: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-phenyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-63: 6-(5-{2-[5-(5-carboxyl-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-phenyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-64: 5-(5-{2-[5-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-phenyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentan-1-ol;

II-65: 5-(5-{2-[5-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-phenyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-66: 5-(5-{2-[5-(4-carboxyl-4,4-dimethyl-pentyl)-tetrahydro-furan-2-yl]-phenyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-67: 5-(5-{2-[5-(5-hydroxy-4,4-dimethyl-pentyl)-furan-2-yl]-phenyl}-furan-2-yl)-2,2-dimethyl-pentan-1-ol;

II-68: 5-(5-{2-[5-(5-hydroxy-4,4-dimethyl-pentyl)-furan-2-yl]-phenyl}-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-69: 5-(5-{2-[5-(4-carboxyl-4,4-dimethyl-pentyl)-furan-2-yl]-phenyl}-furan-2-yl)-2,2-dimethyl-pentanoic acid;

II-70: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-furan-2-yl]-phenyl}-furan-2-yl)-2,2-dimethyl-hexan-1-ol;

II-71: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-furan-2-yl]-phenyl}-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-72: 6-(5-{2-[5-(5-carboxyl-5,5-dimethyl-hexyl)-furan-2-yl]-phenyl}-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-73: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-ethyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-74: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-ethyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-75: 5-(6-{2-[6-(4-carboxyl-4,4-dimethyl-pentyl)-tetrahydro-pyran-2-yl]-ethyl}-tetrahydro-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-76: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-ethyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentan-1-ol;

II-77: 5-(6-{2-[6-(5-hydroxy-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-ethyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-78: 5-(6-{2-[6-(4-carboxyl-4,4-dimethyl-pentyl)-4-oxo-pyran-2-yl]-ethyl}-4-oxo-pyran-2-yl)-2,2-dimethyl-pentanoic acid;

II-79: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-ethyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexan-1-ol;

II-80: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-ethyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-81: 6-(5-{2-[5-(5-carboxyl-5,5-dimethyl-hexyl)-tetrahydro-furan-2-yl]-ethyl}-tetrahydro-furan-2-yl)-2,2-dimethyl-hexanoic acid;

II-82: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-furan-2-yl]-ethyl}-furan-2-yl)-2,2-dimethyl-hexan-1-ol;

II-83: 6-(5-{2-[5-(6-hydroxy-5,5-dimethyl-hexyl)-furan-2-yl]-ethyl}-furan-2-yl)-2,2-dimethyl-hexanoic acid; or

II-84: 6-(5-{2-[5-(5-carboxyl-5,5-dimethyl-hexyl)-furan-2-yl]-ethyl}-furan-2-yl)-2,2-dimethyl-hexanoic acid.

46. A compound of the formula **III**:



III

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

(a) each occurrence of R^1 and R^2 is independently $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, or benzyl; or R^1, R^2, and the carbon to which they are both attached are taken together to form a $(C_3\text{-}C_7)$cycloalkyl group;

(b) each occurrence of m is an independent integer ranging from 0 to 4;

(c) each occurrence of x is independently 2 or 3;

(d) W^1 and W^2 are independently OH, C(O)OH, CHO, $OC(O)R^7$, $C(O)OR^7$, SO_3H,





(e) R^7 is $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1\text{-}C_6)$alkoxy, or phenyl groups;

(f) each occurrence of R^8 is independently H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, or $(C_2\text{-}C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $(C_1\text{-}C_6)$alkoxy, or phenyl groups;

(g) each occurrence of R^9 is independently H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, or $(C_2\text{-}C_6)$alkynyl; and

(h) p is 0 or 1 where the broken line represents an optional presence of 1 or 2 additional carbon-carbon bonds that when present complete 1 or 2 carbon-carbon double bonds.

47. The compound of claim 46, wherein W^1 and W^2 are independently OH, $COOR^7$, or COOH.

48. The compound of claim 46, wherein p is 0.

49. The compound of claim 46, wherein p is 1.

50. The compound of claim 46, wherein the broken line is absent.

51. The compound of claim 46, wherein each occurrence of R^1 and R^2 is independently $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, or benzyl.

52. A compound of the of formula **IV**:



IV

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

(a) each occurrence of R^1 and R^2 is independently $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3\text{-}C_7)$cycloakyl group;

(b) each occurrence of R^{11} and R^{12} is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3\text{-}C_7)$cycloakyl group;

(c) each occurrence of m is independently an integer ranging from 0 to 6;

(d) each occurrence of x is independently and integer from 0 to 4;

(e) W^1 and W^2 are independently $(C_1–C_6)$alkyl, OH, C(O)OH, CHO, $OC(O)R^7$, $C(O)OR^7$, SO_3H,







(f) R^7 is (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6)alkoxy, or phenyl groups;

(g) each occurrence of R^8 is independently H, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, or (C_2-C_6)alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6)alkoxy, or phenyl groups;

(h) each occurrence of R^9 is independently H, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, or (C_2-C_6)alkynyl; and

(a) (i) each occurrence of p is independently 0 or 1 where the broken line represents an optional presence of 1, 2, or 3 additional carbon-carbon bonds that when present form a cycloalkenyl group, a cyclodienyl group, or a phenyl group.

53. The compound of claim 52, wherein W^1 and W^2 are independently OH, $COOR^7$, or COOH.

54. The compound of claim 52, wherein each occurrence of R^1 and R^2 is independently $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, or benzyl.

55. The compound of claim 52, wherein p is 0.

56. The compound of claim 52, wherein p is 1.

57. The compound of claim 52, wherein the broken line is absent.

58. The compound of claim 52, having the formula:



59. The compound of claim 52, having the formula:



60. A pharmaceutical composition comprising a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or a mixture of stereoisomers thereof and a pharmaceutically acceptable vehicle, excipient, or diluent and a pharmaceutically acceptable vehicle, excipient, or diluent.

61. A pharmaceutical composition comprising one or more of the following compounds:

I-114 4-[3-(3-carboxy-3-methyl-butoxy)-propoxy]-2,2-dimethyl-butyric acid,

I-297 5-[2-(5-hydroxy-4,4-dimethyl-pentyloxy)-ethoxy]-2,2-dimethyl-pentan-1-ol,

IV-1 3-{3-[3-(2-Carboxy-2-methyl-propyl)-phenoxy]-phenyl}-2,2-dimethyl-propionic acid,

IV-2 1-{3-[3-(2-hydroxy-2-methyl-propyl)-phenoxy]-phenyl}-2-methyl-propan-2-ol,

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or a mixture of stereoisomers thereof and a pharmaceutically acceptable vehicle, excipient, or diluent.

62. A method for treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

63. A method for treating or preventing a dyslipidemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective

amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

64. A method for treating or preventing a dyslipoproteinemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

65. A method for treating or preventing a disorder of glucose metabolism in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

66. A method for treating or preventing hypertension in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

67. A method for treating or preventing renal disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

68. A method for treating or preventing cancer in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof

69. A method for treating or preventing inflammation in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof

70. A method for treating or preventing impotence in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or

prophylactically effective amount of a compound of comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof

71. A method for treating or preventing a neurodegenerative disease or disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof

72. A method of inhibiting hepatic fatty acid synthesis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

73. A method of inhibiting sterol synthesis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

74. A method of treating or preventing metabolic syndrome disorders in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

75. A method of treating or preventing a disease or disorder that is capable of being treated or prevented by increasing HDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

76. A method of treating or preventing a disease or disorder that is capable of being treated or prevented by lowering LDL levels, which comprises administering to such patient

in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 13, 21, 26, 27, 28, 29, 30, 38, 45, 46, or 52 or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof.

77. A pharmaceutical composition comprising a compound of claim 1, 11, 28, 29, 30, 31, 32, 33, 34, or 35 and a pharmaceutically acceptable vehicle, excipient, or diluent which is administered in combination with a statin.